Literature DB >> 9227841

Effects of nicergoline on age-related decrements in radial maze performance and acetylcholine levels.

R A McArthur1, N Carfagna, L Banfi, S Cavanus, M A Cervini, R Fariello, C Post.   

Abstract

The effects of chronic oral administration of nicergoline (5.0 mg/kg; bid) on locomotor activity, eight-arm radial maze performance plus striatal, cortical, and hippocampal acetylcholine (ACh) levels were examined in young and aged Wistar rats. Chronic nicergoline administration did not modify either the locomotor activity or radial maze learning in young rats. Young rats learned the radial maze procedure rapidly and improved their performance throughout the successive training sessions. Radial maze performance in young rats was characterised by very few arm reentries. Aged rats were hypoactive and did not explore or enter the radial maze arms, and consequently performed poorly in the radial maze throughout the training sessions. Nicergoline treatment did not significantly modify locomotor activity in aged rats. Aged rats treated with nicergoline also performed poorly initially but improved with repeated training in the radial maze. This improvement was associated with an increasing number of arms being entered and very few arm reentries. Reduced acetylcholine (ACh) levels were also associated with age. Aged rats had significantly reduced levels of ACh in the straitum and cortex, but not the hippocampus as compared to young rats. Nicergoline treatment did not change ACh levels in young rats, but substantially restored the reduced ACh levels in aged rats. These results indicate that nicergoline is an effective cognitive enhancer in a learning model of age-related deficits and that these results may be related to changes in the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9227841     DOI: 10.1016/s0361-9230(97)00010-5

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

Review 1.  Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.

Authors:  M Fioravanti; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen.

Authors:  Kelly G Sullivan; Michael Levin
Journal:  J Anat       Date:  2016-04-07       Impact factor: 2.610

Review 3.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

4.  Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study.

Authors:  Jooyeon J Im; Hyeonseok S Jeong; Jong-Sik Park; YoungSoon Yang; Seung-Hee Na; Jin Kyoung Oh; Yong-An Chung; In-Uk Song
Journal:  Dement Neurocogn Disord       Date:  2017-12-31

5.  A clinical trial of nicergoline to prevent temporary threshold shift.

Authors:  Pana Klamkam; Rongrat Pagcharoenpol; Treewit Treesaranuwattana; Pichayen Silpsrikul; Pariyanan Jaruchinda; Piyalarp Wasuwat; Picha Suwannahitatorn
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-25

Review 6.  Therapeutic use of nicergoline.

Authors:  Bengt Winblad; Mario Fioravanti; Tomas Dolezal; Inara Logina; Ivan Gospodinov Milanov; Dinu Cristian Popescu; Alina Solomon
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.